Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 680 publications.
Skip to main content
Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Skoldunger A, Raket LL, Stellick CB, Spackman E, Hlavka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Bruck C, Anderson R, Pemberton-Ross P, Urbich M, Jonsson L. IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease. Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006
Handels R, Herring WL, Grimm S, Skoldunger A, Winblad B, Wimo A, Jonsson L. New IPECAD open-source model framework for the health technology assessment of early Alzheimer's disease treatment: development and use cases. Value Health. 2025 Apr;28(4):511-8. doi: 10.1016/j.jval.2024.07.009
Vickers AD. A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis. Value Health. 2025 Apr;28(4):591-8. doi: 10.1016/j.jval.2025.01.005
Whalley D, Balp MM, Yarr S, Korver D, Sauchelli Toran S, Kohli R, Orfanos P. Psychometric evaluation of the urticaria activity score in chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S506. doi: 10.1016/j.jval.2024.10.3260
Marcano Belisario J, Lunan M, Hawe E, Thurairajah S. Machine learning and artificial intelligence for supporting systematic reviews: a systematic review of recent methodological developments and recommendations for implementation. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S636. doi: 10.1016/j.jval.2024.10.3193
Yee K, Poulos C, Bussberg C, Myers K. Patient characteristics associated with treatment preference for generalized Myasthenia Gravis (gMG): a multivariate analysis. Poster to be given at the ISPOR Europe 2024; November 17, 2025. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Suppl):S524-5.
Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.619
Tavi J, Bahloul D, Kuznik A, Thomas RB, Knight C, Manga N, Sullivan SD. Economic evaluation of dupilumab versus standard of care for the treatment of adult patients with moderate-to-severe prurigo nodularis in the United States. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S104. doi: 10.1016/j.jval.2024.10.543
D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623
Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Johannesen K, Herring WL, Chopra R, Elpers B, Dong O. Using patient-level simulation to estimate long-term survival in idiopathic pulmonary fibrosis. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S459-60. doi: 10.1016/j.jval.2024.10.2345
Burgess B, Leng X, Brizan J, Hawe E. Meta-analysis of pre-post studies: why standardised mean difference should be avoided. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S439. doi: 10.1016/j.jval.2024.10.2243
Sauchelli Toran S, Whalley D, Orfanos P, Kohli R, Balp MM. Clinical relevance of disease activity scores from the patient perspective in chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2024; November 20, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S568. doi: 10.1016/j.jval.2024.10.3550
Sauchelli Toran S, Whalley D, Balp MM, Kohli R, Orfanos P. Content validity of the angioedema activity score from the perspective of adults with chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2024; November 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S516-7. doi: 10.1016/j.jval.2024.10.3307
Clemmet T, Campbell K, Basarir H. Key features of economic models used in submissions to NICE in dermatology indications. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):s155. doi: 10.1016/j.jval.2024.10.784
Neches V, Campbell K, Coll P, Moreno Guillen S, Martinez-Sesmero JM, Lopez Segui F, O'Brien P, Davis A, Anderson SJ, Schroeder M, Vallejo-Aparicio LA. Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.620
Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S494. doi: 10.1016/j.jval.2024.10.2513
Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the economic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S629. doi: 10.1016/j.jval.2024.10.3157
Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the humanistic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S613. doi: 10.1016/j.jval.2024.10.3082
Yubin Sohn A, Khanji C, Nuabor W, Gould T, Kim HK, Barrows SM, Herbel B, Njue A. Effect of adherence to hemophilia drug therapy on outcomes: a systematic literature review. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S634. doi: 10.1016/j.jval.2024.10.3181
Desai A, Dong OM, Gautier S, Johnson T, Wong A, Osman AMY, Harvey J, Tran TH, Holladay Ford DM, Kerr KW, Aggarwal A, Mauskopf J. A systematic review of health economic evaluations of oral nutritional supplements as a single-component or multi-component intervention in older adults with or at risk of malnutrition. Poster presented at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12):S120.
Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S382. doi: 10.1016/j.jval.2024.10.1970
Ronquest N, Zhang Y, Paret K, Armstrong S, Mostovoy L, Berggren R. Identifying the value drivers in obesity treatment: a targeted review of weight loss effects on health economic outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S148. doi: 10.1016/j.jval.2024.10.752
Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S43. doi: 10.1016/j.jval.2024.10.228
Bhushan NL, DeMuro Romano C, Gras-Najjar J, Reno J, Rockwood N, Quattrone W, Adams ET, Kelly B, McLeod L, Bhavnani SP, Bocell FD, Campbell M, Kontson K, Reasner D, Zhang C, Retzky S. Remote-use applications of the amyotrophic lateral sclerosis functional rating scale-revised clinical outcome assessment tool: a scoping review. Value Health. 2024 Oct;27(10):1454-65. doi: 10.1016/j.jval.2024.05.005
Wu B, He X, Tang Z, Martin A, Bracher M, Guo N, Campbell K. Cost-effectiveness analysis of belimumab for the treatment of adults with active lupus nephritis in China. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S77. doi: 10.1016/j.jval.2024.03.405
La E, Sweeney C, Davenport E, Bunniran S. Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S138. doi: 10.1016/j.jval.2024.03.738
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735
Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184
Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D. Preferences for a combination influenza and COVID-19 vaccine: results from a threshold technique study with consumers in the United Kingdom. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S329. doi: 10.1016/j.jval.2024.03.2055
Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D. Healthcare provider preferences for attributes of influenza vaccines in the United States: results from a discrete-choice experiment study. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S338. doi: 10.1016/j.jval.2024.03.2106
Dong OM, Herring W, Chopra P, Elpers B, Johannesen K. A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S148. doi: 10.1016/j.jval.2024.03.2259
Copley-Merriman K, Miller-Wilson LA, Costello J, Schwinn J, Edwards Y. Evidence gap analysis of the burden of illness and treatment of myasthenia gravis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S384-5. doi: 10.1016/j.jval.2024.03.1792
Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236
Graham CN, Erbe AW. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Jain M, Girardi A, Ridley M, Rudell K, Gold A. Impact of caring for persons with schizophrenia: review of burden assessment measures. Poster presented at the ISPOR 2024; May 5, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S34. doi: 10.1016/j.jval.2024.03.181
Masaquel C, Miller-Wilson LA, D'Souza V, Schwinn J, Mina-Osorio P. Evidence gap analysis of the burden of disease in thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S389. doi: 10.1016/j.jval.2024.03.2461
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554
Yande S, Johnson ML, Aparasu RR, Toale K, Wanat M. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins in cancer associated thrombosis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S179. doi: 10.1016/j.jval.2024.03.969
Korgaonkar S, Bentley J, Holmes E, Barnard M, Ramachandran S, Chang Y, Yang Y. Measurement of health insurance literacy and identification of its correlates among working-age cancer survivors in the US. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S345. doi: 10.1016/j.jval.2024.03.2143
Girardi A, Ridley M, Suminski N, Gold A, Rudell K. Saturation reporting in COA development and validation studies: a scoping overview. Poster presented at the ISPOR 2024; May 5, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S54. doi: 10.1016/j.jval.2024.03.2199
Bonner C, Pilar M, Jacobs S, Samsell B, Hollis K. Optimizing drug value and access using implementation science. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S318. doi: 10.1016/j.jval.2024.03.2000
O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580
Petit I, Eliasson L, Romero B, Patel C, Di Rosa A, Quinn J. Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S309. doi: 10.1016/j.jval.2024.03.1955
Miles L, Mauskopf J. Enhancing the value and usefulness of data extracted from an economic systematic literature review. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S407. doi: 10.1016/j.jval.2024.03.1916
Herring WL, Wittrup-Jensen V, Fox L. Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S76. doi: 10.1016/j.jval.2024.03.403
Slota C, Norcross L, Comerford E, Sasane M, Zheng Y, Gnanasakthy A. Critical comments by Food and Drug Administration Reviewers on patient-reported outcomes in Food and Drug Administration Regulatory Submissions (2018-2021) [Editor's Choice]. Value Health. 2024 Jun;27(6):755-66. doi: 10.1016/j.jval.2024.02.011
McLeod L, Ervin C, Fehnel SE, Eremenco S, Carson RT, Hanlon J, Coons SJ. Psychometric evaluation of the diary for irritable bowel syndrome symptoms-constipation in a prospective observational study. Value Health. 2024 May;27(5):614-22. doi: 10.1016/j.jval.2024.01.013